A double mutation of BRAF L597Q and V600E in situ and solitary brain metastasis of occult papillary thyroid carcinoma
A case report
Ling Chen, MDa, Yue Wu, BSB, Medc, Huili Bai, MSSc, Huandong Liu, BSB, Medd, Xiaosong Li, MD, PhDc,∗

Abstract
Rationale: The rare BRAF L597Q (c.T1790A) point mutation has been previously reported in childhood acute lymphoblastic leukemia. We present the first rare case of occult papillary thyroid carcinoma with BRAF L597Q mutation in a Tibetan patient.

Patient concerns: A 57-year-old male patient presented with a protruding mass on the left forehead for 2 years and numbness in the right limb for 3 weeks.

Diagnoses: The patient had a double mutation of BRAF L597Q and V600E in 2 separate lesions at thyroid and brain, the immunohistochemical staining showed that the cytokeratin (CK), thyroglobulin (Tg) and thyroid transforming factor-1 (TTF-1) were immunoreactive. All the findings supported the diagnosis of solitary brain metastasis of occult papillary thyroid carcinoma.

Interventions: The patient underwent left frontal lobe metastasis (thyroid cancer) resection that involved craniectomy and artificial skull repair.

Outcomes: During the 24-month follow-up, no postoperative complications or recurrence and metastasis were found.

Lessons: This is the first case of solitary brain metastasis of occult papillary thyroid carcinoma with double mutation of BRAF L597Q and V600E in 2 separate lesions reported in the literature. Our study extends the disease spectrum of occult papillary thyroid carcinoma and suggests that the BRAF L597Q mutation might play a specific role in inducing the solitary brain metastasis of occult papillary thyroid carcinoma in a Chinese Tibetan patient, but the detailed molecular mechanism remains to be confirmed by a large number of functional experiments and clinical research.

Abbreviations: NGS = next generation sequencing, PTC = papillary thyroid carcinoma, US-FNA = ultrasound-guided fine-needle aspiration.

Keywords: brain metastasis, next generation sequencing, papillary thyroid carcinoma, thyroid cancer

1. Introduction
The global incidence of thyroid cancer (TC) continues to rise sharply, mainly due to the advent of advanced molecular diagnostic technologies.[1] The 4 major subtypes of thyroid cancer are papillary thyroid carcinoma (PTC), anaplastic thyroid carcinoma, follicular thyroid carcinoma and medullary thyroid carcinoma.[2] PTC is the most common solid tumor in the human endocrine system, which occurs in more than 90% of all thyroid malignancies, and the incidence of PTC has increased rapidly in recent years.[3–4]
According to the National Comprehensive Cancer Network (NCCN) Guidelines Insights (Thyroid Carcinoma, Version 2.2018.) and other studies,[7,8] screening for thyroid cancer has been divided into routine testing and molecular testing. The routine testing is accomplished by radionuclide scanning, B-ultrasound, magnetic resonance imaging (MRI), X-ray examination, computed tomography (CT), and thyroid-related hormone detection. The molecular testing consists of genetic testing or testing of other molecular markers by fine-needle aspiration (FNA). The FNA with ultrasound guidance is gradually becoming the preferred method for assessing suspicious thyroid nodules. According to the 2017 Bethesda System for Reporting Thyroid Cytopathology, the cytological examination of FNA specimens is usually divided into 6 categories.[9,10] In recent years, Chinese scholars have established a new sensitive imaging technique, which uses deep convolutional neural network (DCNN) models to increase the diagnostic accuracy by analyzing the sonographic imaging data of clinical ultrasounds.[11]

Some gene mutations[12–15] have played an important role in the proliferation, migration and invasion of thyroid cancer, such as BRAF, TERT, APC and CTNNB1 mutations; BRAF, ALK and NTRK fusion; as well as RET/PTC rearrangements. However, the most common type of genetic mutation is BRAF V600E. The solid tumor is highly differentiated, minimally malignant and often has a favorable prognosis; therefore, the best treatment for PTC is surgical resection with the 5-year survival rate up to 90%.[16–18] It was reported that up to 90% of patients had their thyroid removed by surgery, which may lead to additional medical costs and psychological stress.[19–21] The most common metastatic sites of thyroid cancer are lungs and bone with extremely rare metastases in brain.[22,23] This study reports the first case of solitary brain metastasis from occult papillary thyroid carcinoma in a Chinese Tibetan patient.

2. Case presentation

A 57-year-old Tibetan male patient came to the hospital with numbness in the right limb for 3 weeks. The examination revealed that the patient had normal development, adequate nutrition, no obvious acute or chronic medical conditions, and no obvious abnormalities in heart, lungs, liver, gallbladder, pancreas, spleen, and kidney. The bilateral Babinski signs were negative, and there were no other special manifestations, except for the right limb muscle strength (grade IV) and a protruding mass on the left forehead for 2 years. The CT, MRI, color ultrasound diagnosis, ultrasound-guided fine-needle aspiration and hematoxylin-eosin staining staining were used to for morphological examination. The specific expression of thyroid cancer-related proteins (cytokeratin, CK; thyroglobulin, Tg and thyroid transforming growth factor) were negative.

![Figure 1. Preoperative skull CT/MRI scan and intraoperative photographs during resection and debulking. (A): Irregular bone destruction of the left frontal bone, the range is about 5.7 cm × 6.3 cm. (B): Irregular masses are seen in the left frontal cranial and subscalp, the size is about 4.9 cm × 5.4 cm, it is uneven and obviously strengthened, and the center line structure is skewed to the right. (C): The outer plate of skull, raised bone (4.8 cm × 5.2 cm) surface of the skull’s outer plate is uneven, showing cancellous bone. (D): The tumor isolated from the operation is hard in texture, about 5.7 cm × 6.3 cm in size.](image_url)
factor-1, TTF-1) were detected by the immunohistochemical analysis. The mutation of BRAF gene was found by amplification refractory mutation system-polymerase chain reaction, Sanger sequencing and next generation sequencing (NGS) analyses.

The preoperative skull CT and MRI scan showed a 9.3 cm × 8.1 cm mass in the left frontal cortex (Fig. 1A and B). The skin on the surface of the mass was normal and hard in texture. The preoperative conventional color ultrasound diagnosis showed...
that the size of the bilateral thyroid was normal, and the echo in the right lobe was uneven. Left frontal lobe metastasis (thyroid cancer) resection with craniectomy and artificial skull repair was suggested by the multi-disciplinary team (MDT). During the operation we observed that the scalp tissue and the left frontal skull were adhered, and the surface of the protruding bone tissue was uneven and loose. The hyperplasia of the inner and outer plates of the skull could be seen (Fig. 1C). The tumor tissue was white and solid, and there was no adhesion with the surrounding brain tissue (Fig. 1D). After the surgery, the completely excised tumor tissue was sent to the Clinical Molecular Medicine Testing Center for molecular pathology diagnosis. The preoperative conventional color ultrasound diagnosis showed that the size of the bilateral thyroid was normal, and the echo in the right lobe was uneven. A mass (0.7 cm × 0.5 cm) was visible, with oval shape and clearly defined border (Fig. 2A). Ultrasound-guided fine-needle aspiration was used to biopsy the thyroid nodules. The results showed that these tumor cells were relatively uniform in size with round nuclei, and small nucleoli was observed in some tumor cells. (Fig. 2B).

Hematoxylin-eosin staining staining of the brain specimen showed that the nucleus of the cancer cells had the texture of the ground glass. The nuclear grooves and pseudo-inclusions in the nucleus were clearly observed, and psammoma bodies were seen in the interstitial tissue (Fig. 3A). In general, the cytoelement (CK), thyroglobulin (Tg) and thyroid transforming factor-1 (TTF-1) in papillary thyroid carcinoma were strongly immunohistochemically positive, in this patient. The immunohistochemical staining showed that the CK, Tg and TTF-1 were immunoreactive (Fig. 3B, C and D). The amplification refractory mutation system-polymerase chain reaction, Sanger and NGS analyses showed that the patient had double mutations of BRAF L597Q and V600E in two separate lesions (Fig. 4). The BRAF V600E (chr7:140453136 c.1799T>A) mutation was located in situ of thyroid cancer (Fig. 4A and C), but the BRAF L597Q (chr7:140453145 c.1790T>A) mutation was located in the brain metastases (Fig. 4B and D). The abundances of BRAF L597Q and V600E were 36.9% and 8.1% which was determined by NGS, respectively, and they were successfully verified by the gold standard for gene sequencing (Sanger sequencing).

Figure 4. Genetic diagnosis results. (A: BRAF V600E (c.1799T>A) mutation tested by Sanger sequencing in situ. B: BRAF L597Q (c.1790T>A) mutation tested by Sanger sequencing in metastases. C: BRAF V600E (c.1799T>A) mutation tested by NGS in situ, and D: BRAF L597Q (c.1790T>A) mutation tested by NGS in metastases.)
In this rare case report, all the above findings supported the diagnosis of solitary brain metastasis of occult papillary thyroid carcinoma. There were no adverse and unanticipated events during the peri-operative period. During the 24-month follow-up, no postoperative complications or recurrence and metastasis were observed.

3. Discussion

According to the recommendations of the American Thyroid Association (ATA), FNAB is currently the most accurate method to identify benign or malignant thyroid nodules. However, there are still some cases that cannot be defined as benign or malignant,[24] because the diameter of the thyroid nodules is less than 1 cm. Benign or malignant cells related to thyroid cancer can be detected by molecular markers, such as BRAF mutation, RAS mutation and RET/PTC rearrangement.[25] Some guidelines (2017 Bethesda guidelines and 2019 NCCN) have recommended that molecular marker testing should be used for the assessment of benign or malignant thyroid nodules, especially in combination with genetic testing. The combined results could significantly improve the negative predictive value of cancer, which might reduce unnecessary surgery. One study reported that BRAF, PAX8/PPARγ and RET/PTC could increase the diagnostic specificity of PTC up to 100%.[26] It was recognized that genetic testing was the prerequisite for individualized treatment and could be used to assess the sensitivity of targeted drugs, develop new drugs and explore combined drug treatment. Genetic testing could also help assess the risk of thyroid cancer recurrence and provide a basis for postoperative management. Comprehensive genomic analysis can identify new treatment paradigms to address the limited options and poor prognosis of patients with primary unknown site cancer. It is also possible to reduce the regular expenses and time-consuming search for the cancer’s anatomic site of origin.[27]

However, genetic diagnosis cannot meet the clinical needs of including or excluding thyroid cancer and preoperative risk stratification of thyroid cancer. Although the positive results of FNA may be useful for individualized treatment of thyroid cancer, while the negative genetic results might not be an indicator of that cannot benefit from it.[28]

The BRAF V600E or other mutations (e.g., TERT promoter mutation or RET/PTC fusions and so on) could demonstrate mutations typical of classic PTC.[29] In this study, 59 high-frequency mutations and targeted drug-related genes (e.g., BRAF, TERT, PTEN, TP53, PIK3CA, RAS, RET and so on) that may be related to thyroid cancer was determined by NGS, but the genetic test results showed that only BRAF gene mutations (L597Q and V600E in 2 separate lesions) occurred in the patient. Although the BRAF V600E (c.1799T>A) mutation is the most common type of genetic mutation in thyroid cancer, the BRAF L597Q (c.T1790A) mutation is extremely rare.

4. Conclusion

The rare BRAF L597Q (c.T1790A) point mutation, which is regarded as an oncogene, has been previously reported and described in childhood acute lymphoblastic leukemia.[30,31] Additionally, other studies have reported that the rare BRAF (c.T1790A) point mutation might have some correlation with tumor metastasis in melanomas and lymphoblastic leukemia.[32,33] Therefore, we hypothesize that the BRAF L597Q mutation might play a specific role in inducing the solitary brain metastasis of occult papillary thyroid carcinoma in Chinese Tibetan patient, and a large number of functional experiments and clinical studies is needed to confirm the decisive role of BRAF L597Q mutation in the brain metastasis of occult thyroid cancer. In addition, we hope our research will lead to the development of targeted therapeutics in future.

Author contributions

YW and XSL designed the study and take responsibility for the integrity and accuracy of the data analysis. LG, HL and HD performed the main experiments and analysed the data; XSL drafted and revised the manuscript. All authors contributed to this manuscript. All authors read and approved the final manuscript.

Conceptualization: Xiaosong Li.
Methodology: Huili Bai, Huandong Liu.
Resources: Huandong Liu.
Software: Yue Wu.
Writing – original draft: Ling Chen, Yue Wu.
Writing – review & editing: Xiaosong Li.

References

[1] Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016;388:2783–95.
[2] Tambhe S, Gharib H. Thyroid nodule update on diagnosis and management. Clin Diabetes Endocrinol 2016;2:17doi: 10.1186/s40842-016-0035-7.
[3] Lewinski A, Adamczewski Z, Zygmunt A, et al. Correlations between molecular landscape and sonographic image of different variants of papillary thyroid carcinoma. J Clin Med 2019;8:1916doi: 10.3390/jcm8111916.
[4] Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic” – screening and overdiagnosis. N Engl J Med 2014;371:1765–7.
[5] Kim TY, Kim WG, Kim WB, et al. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab 2014;29:217–25.
[6] Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014;99:E276–85.
[7] Haddad RI, Nasr C, Bischoff L, et al. NCCN guidelines insights: thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw 2018;16:1429–40.
[8] Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review 1975-2015 based on November 2017 SEER data submission posted to the SEER web site April 2018. Bethesda, MD: National Cancer Institute; 2018.
[9] Layfield LJ, Gibas ES, Gharib H, et al. Thyroid aspiration cytology: current status. CA Cancer J Clin 2009;59:99–110.
[10] Gibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017;27:1341–6.
[11] Li X, Zhang S, Zhang Q, et al. Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study. Lancet Oncol 2019;20:193–201.
[12] Alexander EK, Kennedy GC, Baloch ZW. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012;367:705–15.
[13] The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–90.
[14] Yarchoan M, Li Volsi VA, Brose MS. BRAF mutation and thyroid cancer recurrence. J Clin Oncol 2015;33:7–8.
[15] Ryder M, Bible KC. Mutated BRAF and personalised medicine in differentiated thyroid cancer. Lancet Oncol 2016;17:e1181–3.
[16] Gyorky DE, Untch B, Turtle RM, et al. Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. Ann Surg Oncol 2013;20:2285–9.
[17] Kim SH, Roh JH, Gong G, et al. Differences in the recurrence and survival of patients with symptomatic and asymptomatic papillary thyroid
carcinoma: an observational study of 11,263 person-years of follow-up. Thyroid 2016;26:1472–9.

[18] Brose MS, Cabanillas ME, Cohen EEW, et al. Vemurafenib in patients with BRAFTV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:1272–82.

[19] Cho BY, Choi HS, Park YJ, et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013;23:797–804.

[20] The Lancet. Thyroid cancer screening. Lancet 2017;389:1934.

[21] Lee JH, Shin SW. Overdiagnosis and screening for thyroid cancer in Korea. Lancet 2014;384:1348.

[22] Mydlarz WK, Wu J, Aygun N, et al. Management considerations for differentiated thyroid carcinoma presenting as a metastasis to the skull base. Laryngoscope 2007;117:1146–52.

[23] Tagle P, Villanueva P, Torresalba G, et al. Intracranial metastasis or meningioma? An uncommon clinical diagnostic dilemma. Surg Neurol 2002;58:241–5.

[24] Gomez Saez JM. Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics 2011;12:597–608.

[25] Nikiforov YE, Baloch ZW, Hodak SP, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features. JAMA Oncol 2018;4:1325–6.

[26] Hou P, Liu D, Xing M. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia 2007;21:2216–8.

[27] Jeffrey SR, Kai W, Laurie G, et al. Comprehensive genomic profiling of carcinoma of unknown primary site new routes to targeted therapies. JAMA Oncol 2015;1:40–9.

[28] Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol 2019;5:204–12.

[29] Nikiforov YE, Baloch ZW, Hodak SP, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features. JAMA Oncol 2018;4:1325–6.

[30] Wellcome Trust Sanger Institute. COSMIC (Catalogue of Somatic Mutations in Cancer Web site). Mutation overview BRAF p.L597Q (substitution–missense). http://cancer.sanger.ac.uk/cosmic/mutation/overview/id51125. Accessed June 7, 2013.

[31] Grätz V, Angün O, Haase O, et al. Response of BRAF(L597Q)-mutant melanoma to trametinib: Targeted melanoma therapy beyond BRAF (V600) mutations. Hautarzt 2016;67:648–52.

[32] Shaterian A, Bota D, Leis A. Expression of the BRAF L597Q mutation in sporadic neurofibromas of the upper extremity. Exp Mol Pathol 2017;103:276–8.